Lipoprotein-associated phospholipase A2 activity and low-density lipoprotein subfractions after a 2-year treatment with atorvastatin in adolescents with type 1 diabetes by Krebs, Andreas et al.
J Pediatr Endocrinol Metab 2016; 29(10): 1181–1186
†Deceased
*Corresponding author: Prof. Dr. Karl Otfried Schwab, MD, 
Department of Pediatrics and Adolescent Medicine, University 
Medical Center, Mathilden Street 1, 79106 Freiburg, Germany, 
Phone: +4976127044821, Fax: +4976127044140,  
E-mail: karl.otfried.schwab@uniklinik-freiburg.de
Andreas Krebs, Juergen Doerfer and Alexandra Krause: Department 
of Pediatrics and Adolescence Medicine, University Hospital, 79106 
Freiburg, Germany
Juergen Grulich-Henn: Department of Pediatrics and Adolescence 
Medicine, University Hospital, 69120 Heidelberg, Germany
Martin Holder and Wolfgang Hecker: Children’s Hospital, 
Olgahospital, 70176 Stuttgart, Germany
Kai Lichte: Clinic for Pediatrics and Adolescent Medicine, 
Schwarzwald-Baar Medical Center, 78050 Villingen-Schwenningen, 
Germany
Arno Schmidt-Trucksaess: Institute of Exercise and Health Sciences, 
University of Basel, Basel, Switzerland
Karl Winkler: Department of Clinical Chemistry, University Hospital, 
79095 Freiburg, Germany
Andreas Krebs, Juergen Doerfer, Alexandra Krause, Juergen Grulich-Henn, Martin Holder, 
Wolfgang Hecker†, Kai Lichte, Arno Schmidt-Trucksaess, Karl Winkler and Karl Otfried Schwab*
Lipoprotein-associated phospholipase A2 activity 
and low-density lipoprotein subfractions after a 
2-year treatment with atorvastatin in adolescents 
with type 1 diabetes
DOI 10.1515/jpem-2015-0365
Received September 9, 2015; accepted August 29, 2016
Abstract
Background: The objective of the study was to assess the 
effect of atorvastatin on inflammation markers and low-
density lipoprotein (LDL) subfractions.
Methods: In a prospective, randomized, double-blind 
pilot study involving 28 adolescents with type 1 diabetes 
(T1D), lipoprotein-associated phospholipase A2 (Lp-PLA2) 
activity, high-sensitivity C-reactive protein (hsCRP), and 
subfractions of LDL were measured at baseline, after 1 year 
and 2 years of treatment with atorvastatin (10 mg/day) vs. 
placebo.
Results: For the atorvastatin group, we found posttreat-
ment reductions of Lp-PLA2 activity (p < 0.001), LDL 
cholesterol (p = 0.001), non-small dense LDL cholesterol 
(p < 0.001), total cholesterol (p < 0.001), and apolipopro-
tein B (apo B) (p < 0.001), whereas small dense LDL cho-
lesterol and hsCRP did not change significantly.
Conclusions: In adolescents with T1D, long-term treat-
ment with atorvastatin is safe and may reduce cardiovas-
cular risk by significant decreases of Lp-PLA2 activity and 
LDL cholesterol.
Keywords: atorvastatin; inflammatory markers; LDL sub-
fractions; type 1 diabetes.
Introduction
The incidence of Type 1 diabetes (T1D) is increasing, 
with a number of acute and chronic complications. Ath-
erosclerosis is one of the most important long-term con-
sequences of T1D [1, 2]. In addition, it is recognized that 
inflammatory processes are an essential component of 
both atherogenesis and T1D [3, 4]. Lipoprotein-associated 
phospholipase A2 (Lp-PLA2) is secreted by inflammatory 
cells including macrophages and represents an important 
marker of vascular inflammation [5]. Its local coronary 
production was demonstrated in patients with early coro-
nary atherosclerosis [6]. Two-thirds of circulating Lp-PLA2 
is linked to low-density lipoprotein (LDL) and one-third to 
high-density lipoprotein (HDL) [7]. In the general popu-
lation, Lp-PLA2 activity has been found to be associated 
with increased cardiovascular risk and cardiac mortality 
[8, 9]. Also in adults with type 2 diabetes, Lp-PLA2 activ-
ity has been identified as an independent risk factor and 
predictor for coronary heart disease and cardiovascu-
lar outcome [10, 11]. Although coronary heart disease is 
a major cause of long-term mortality in adults with T1D 
[12], there is comparatively little data available about the 
influence of Lp-PLA2 on the development of atheroscle-
rotic vascular disease in these patients [13, 14]. Moreover, 
it must be noted that information from the literature on 
a relationship between Lp-PLA2 and atherosclerosis for 
children and adolescents with T1D is weak or lacking so 
far. Due to the close interrelation between Lp-PLA2 activ-
ity and increased cardiovascular risk, suitable therapeutic 
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agents have been evaluated in order to mitigate the risk. 
Thus, it could be shown that various lipid-lowering drugs 
and a novel Lp-PLA2 inhibitor are able to reduce apolipo-
protein B (apo B)-associated Lp-PLA2 activity [15–17].
The primary objectives of the present study were to 
assess Lp-PLA2 activity, high-sensitivity C-reactive protein 
(hsCRP), LDL subfractions, and the effect of a 2-year treat-
ment with atorvastatin relative to these parameters in 
adolescents with T1D.
Materials and methods
Study design and patients
The present article is based on a prospective, randomized, placebo-
controlled, double-blind multicenter study entitled “Vasoprotection 
by atorvastatin in children and adolescents with T1D, a 2-year pilot 
study” (ATV 03-005G). The protocol was approved by the Ethics 
Committee at the Albert-Ludwigs-University of Freiburg (registration 
number: 243/03; German Clinical Trials Register: DRKS00000297, 
Registry URL: http://www.germanctr.de) and all participants or their 
parents signed an informed consent. At the centers for Pediatrics 
and Adolescent Medicine of the University Medical Centers Freiburg, 
Heidelberg, and the Olgahospital Stuttgart in Germany, 270 children 
and adolescents with T1D were screened in terms of their eligibility 
for participation. The diagnosis T1D was made following the guide-
lines of the American Diabetes Association (ADA) [18]. For ethical 
reasons and to avoid unnecessary treatment with atorvastatin, only 
adolescents were enrolled who showed a median carotid intima-
media thickness  ≥ 75th percentile (Schmidt-Trucksäss A) compared to 
healthy controls [19]. Of 270 screened patients, 28 were eligible for 
inclusion in the study and randomly allocated to two study groups 
(10 patients received placebo and 18 patients received 10  mg ator-
vastatin/day). In the course of the study there were four drop-outs 
in the atorvastatin group due to one fatal traffic accident and three 
cases of non-compliance (inadequate intake of the study medication, 
failure to attend the study visits) and two drop-outs in the placebo 
group, one because of poor glycemic control with HbA1c >9.5% meas-
ured twice within a period of 4 weeks and one because of inadequate 
intake of the study medication. The pharmacy at the University Hos-
pital in Freiburg provided the randomization code assignment as 
well as packaging, blinding, and labeling of the study medication. 
During the whole study period of 24 months, 12 study visits were con-
ducted for assessments of clinical, laboratory, and safety parameters.
Study parameters and laboratory analyses
Standard deviation score (SDS) of the body mass index (BMI, kg/m2) 
was calculated using normal values of German children and ado-
lescents [20]. Blood pressure level is composed of the average 
derived from three measurements with a Dinamap pediatric  monitor 
( Critikon, Tampa, FL, USA). Pulse pressure was assessed from the 
difference between systolic and diastolic blood pressure. Labora-
tory determinations were done after an overnight fasting period and 
evaluated centrally at the Department of Clinical Chemistry, Univer-
sity Medical Center Freiburg, Germany.
Lipids and lipoproteins
Cholesterol and triglycerides were determined enzymatically with 
the CHOD-PAP and GPO-PAP method with commercially available 
reagents, respectively (Wako Chemicals, Osaka, Japan). The con-
centration of apo B was assessed by turbidimetry (A 640 analyzer, 
Olympus, Tokyo, Japan) using polyclonal antiserum (Greiner Bio-
chemica, Flacht, Germany). LDL particles were analyzed by equilib-
rium density gradient ultracentrifugation (Beckman Optima LE-80K 
ultracentrifuge; Beckman Coulter Inc., Fullerton, CA, USA) using the 
following densities: 1.019–1063 kg/L (total LDL), <1.031 kg/L (LDL-1), 
1.031–1.034 kg/L (LDL-2), 1.034–1.037 kg/L (LDL-3), 1.037–1.040 kg/L 
(LDL-4), 1.040–1.044 kg/L (LDL-5), and >1.044 kg/L (LDL-6). Athero-
genic LDL-5 and LDL-6 were summarized as small dense LDL (sdLDL) 
particles and LDL-1–LDL-4 as non-sdLDL [21].
Inflammation markers
High-sensitivity C-reactive protein (hsCRP) was measured using 
a commercially available immunonephelometric assay kit (Dade 
Behring GmbH, Eschborn, Germany). Immunonephelometric assays 
were performed on an Olympus AU680 analyzer (Beckman Coulter 
Inc., Fullerton, CA, USA).
Lp-PLA2 is also denoted as platelet-activating factor acetyl-
hydrolase (PAF-AH). The activity of Lp-PLA2 was measured on an 
Olympus AU680 analyzer (Beckman Coulter Inc., Fullerton, CA, USA) 
using 1-myristoyl-2-(4-nitrophenylsuccinyl)-sn-glycero-3-phospho-
cholin as substrate releasing 4-nitrophenylsuccinate. The eventually 
resulting 4-nitrophenol was then determined photometrically. Inter-
assay coefficient of variance for Lp-PLA2 was <5% [22].
Statistical analysis
Comparison of study groups was calculated according to the inten-
tion-to-treat principle. Data are shown as median with the 95% con-
fidence interval in brackets (CI). Differences between groups were 
analyzed with the non-parametrical Mann-Whitney U-test. Changes 
of parameters within a study group in the course of the study were 
analyzed with the Friedman test comparing data between baseline, 
1 year, and study end after 2 years. The rank correlation coefficient 
was calculated according to Spearman. A p-value <0.05 was accepted 
for statistical significance. The SPSS 20.0 statistical program 
( Chicago, IL, USA) was used for all analyses.
Results
Table  1 compares characteristics of children and adoles-
cents with T1D who received either atorvastatin (10 mg/day) 
or placebo. Neither groups differed significantly.
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Table 2 compares the course of lipid and lipoprotein 
levels between the atorvastatin and the placebo group at 
baseline (atorvastatin group n = 18, placebo group n = 10), 
after 1 year (atorvastatin group n = 16, placebo group n = 9), 
and after 2 years (atorvastatin group n = 14, placebo group 
n = 8). In the atorvastatin group, total cholesterol, apo 
B, and total low-density lipoprotein cholesterol (LDL-C) 
were significantly reduced. Non-sdLDL-C was also signifi-
cantly reduced but closely parallel to the reduction of total 
LDL-C. In contrast, the level of sdLDL-C remained more or 
less the same. In the placebo group, total cholesterol was 
significantly reduced, but all other analyzed lipid param-
eters showed only non-significant changes.
Lp-PLA2 was significantly reduced by atorvastatin 
and increased non-significantly in the placebo group. The 
ratio of Lp-PLA2 to LDL-C increased (p < 0.001) during the 
course of the study (Table 3).
Correlations between sdLDL and triglycerides and 
sdLDL and HDL-C were tested using the Spearman 
rank correlation coefficient. There was no significant 









Age, years   14.4 (13.9–15.8)  15.9 (13.8–16.6)  NS
Diabetes duration, years   4.9 (4.0–7.6)  5.5 (3.5–8.9)  NS
HbA1c,%   8.3 (7.7–8.8)  8.2 (7.0–9.0)  NS
Insulin, IU/kg/day   0.70 (0.63–0.95)  0.90 (0.70–1.04)  NS
BMI-SDS   0.65 (0.34–1.03)  0.50 (0.48–0.79)  NS
Systolic blood pressure, mmHg   121 (112–126)  126 (117–132)  NS
Diastolic blood pressure, mmHg  70 (65–73)  69 (65–76)  NS
Pulse pressure, mmHg   51 (43–57)  53 (47–61)  NS
Data are medians (95% CI). aMann-Whitney U-test was used for comparison between groups; NS, not significant; HbA1c, glycated hemoglobin 
A1c; BMI-SDS, body mass index-standard deviation score.
Table 2: Lipoproteins at baseline and during the administration of either atorvastatin (10 mg/day) or placebo in children with type 1 
diabetes.
Parameters   Baseline  1 year  2 years  p-Valuea
non-sdLDL-C, mg/dL
 Atorvastatin   40 (33–50)  29 (22–36)  25 (21–29)  <0.001
 Placebo   38 (32–44)  32 (25–44)  33 (28–47)  NS
sdLDL-C, mg/dL
 Atorvastatin   14 (12–16)  12 (10–14)  13 (9–20)  NS
 Placebo   16 (12–18)  13 (11–18)  15 (13–21)  NS
Total cholesterol, mg/dL
 Atorvastatin   172 (160–193)  143 (127–153)  134 (124–151)  <0.001
 Placebo   164 (145–202)  153 (133–181)  162 (148–205)  NS
LDL-C, mg/dL
 Atorvastatin   85 (77–105)  64 (48–76)  55 (48–71)  <0.01
 Placebo   85 (70–99)  75 (58–97)  84 (72–107)  NS
apo B, mg/dL
 Atorvastatin   65 (57–79)  53 (43–62)  46 (40–62)  <0.001
 Placebo   66 (56–77)  61 (48–77)  68 (56–81)  NS
HDL-C, mg/dL
 Atorvastatin   57 (53–66)  54 (52–64)  52 (47–60)  NS
 Placebo   67(57–83)  50 (40–70)  55 (47–70)  0.030
Triglycerides, mg/dL
 Atorvastatin   73 (59–94)  68 (55–111)  54 (41–98)  NS
 Placebo   50 (45–68)  56 (50–64)  65 (56–75)  NS
Data are medians (95% CI). aFriedman test; NS, not significant; LDL-C, low-density lipoprotein cholesterol; non-sd LDL-C, non-small dense 
(LDL 1-4) LDL-C; sdLDL-C, small dense (LDL 5 and 6) LDL-C; HDL-C, high-density lipoprotein cholesterol; apo B, apolipoprotein B.
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correlation both at baseline (total group) and after 2 years 
(atorvastatin group).
No adverse event occurred in either the atorvastatin 
group or the placebo group during the course of the study.
Discussion
The main outcomes of this study were significant reduc-
tions of Lp-PLA2 activity and LDL-C during the long-term 
treatment with low-dose atorvastatin in adolescents with 
T1D. Statins are increasingly used for the treatment of high 
LDL levels in children and adolescents, but should not be 
prescribed before 10 years of age in boys and only after the 
onset of menses in girls. The recommended daily dose of 
atorvastatin for children is 10–20 mg and number and type 
of adverse effects are comparable to those of adults [23]. A 
similarly positive safety profile of atorvastatin 10 mg and 
80 mg has been confirmed in numerous clinical trials in 
adult populations [24]. With regard to the long-term safety 
of statins, particular attention shall be paid to elevations 
of liver transaminases and creatine kinase using regular 
monitoring. Although cases of rhabdomyolysis are rare, 
patients and their parents should be informed about the 
muscle-related side effects of statins [23].
In terms of Lp-PLA2 activity in children and adoles-
cents, it has been reported that obese children and ado-
lescents showed significantly higher levels than healthy 
controls, [25] and moreover, an association between 
increased Lp-PLA2 concentrations and higher BMI 
percentiles [26]. In male schoolchildren, Lp-PLA2 activity 
was inversely and independently associated with physi-
cal activity emphasizing the importance of exercise for 
the prevention of atherosclerosis [27]. Lp-PLA2 activity 
was also significantly increased in children and adoles-
cents with heterozygous familial hypercholesterolemia in 
comparison to unaffected siblings and was significantly 
reduced by pravastatin therapy, whereby the increase of 
Lp-PLA2 activity was probably due to the close binding 
to the markedly increased LDL particles in this disease 
[28]. However, studies investigating Lp-PLA2 activity in 
children and adolescents with T1D have not been pub-
lished yet. In adults with T1D, levels of Lp-PLA2 activity 
were significantly higher than in controls indicating that it 
may be related to low-grade inflammation or to the higher 
risk of developing cardiovascular disease established in 
patients with T1D [29, 30]. In addition to the significant 
reduction of Lp-PLA2 and LDL-C, we have also established 
an increasing ratio of Lp-PLA2 activity to LDL-C indicating 
that the decrease in LDL-C was proportionally greater than 
the decrease in Lp-PLA2 activity. In various publications, 
the reduction of Lp-PLA2 activity by statins is in the range 
from 20% to 40% [15, 16]. In line with this, our diabetic 
patients in the atorvastatin group revealed a decrease 
of Lp-PLA2 activity of 21%, whereas the patients receiv-
ing placebo showed no significant change of Lp-PLlA2 
activity during the study period. Although two-thirds of 
plasma Lp-PLA2 is bound to LDL particles, only 1 LDL par-
ticle in 1000 obtains a molecule of Lp-PLA2 [7]. This could 
also be a reason for a more effective reduction of LDL-C 
Table 3: Inflammation markers and risk factors at baseline and during the administration of either atorvastatin (10 mg/day) or placebo in 
children with type 1 diabetes. 
Parameters   Baseline  1 year  2 years  p-Valuea
hsCRP, mg/L
 Atorvastatin  0.45 (0.35–1.01)  0.40 (0.34–1.20)  0.60 0.37–0.94)  NS
 Placebo   0.30 (0.12–1.26)  0.70 0.07–3.03)  0.45 (0.17–2.20)  NS
Lp-PLA2 activity, U/L
 Atorvastatin  403 (364–436)  331 (295–360)  318 (295–358)  <0.001
 Placebo   364 (338–427)  397 (343–445)  389 (347–468)  NS
Lp-PLA2 activity/LDL-C
 Atorvastatin  4.6 (4.2–6.0)  5.6(5.0–8.3)  6.1 (5.5–7.9)  <0.001
 Placebo   4.4 (4.2–5.0)  5.7(4.3–6.8)  5.2 (3.8–7.9)  NS
HbA1c,%
 Atorvastatin  7.9 (7.4–8.5)  8.2 (7.7–8.7)  8.3 (7.7–9.2)  NS
 Placebo   8.2 (7.0–9.0)  7.8 (6.9–8.9)  8.7 (7.5–9.3)  NS
Syst. BP, mmHg
 Atorvastatin  121 (113–126)  123 (116–134)  118 (108–125)  NS
 Placebo   126 (117–132)  121 (114–130)  120 (114–130)  NS
Data are medians (95% CI). aFriedman test; NS, not significant; LDL-C, low-density lipoprotein cholesterol; hsCRP, high sensitivity C-reactive 
protein; Lp-PLA2, lipoprotein-associated phospholipase A2; HbA1c, glycated hemoglobin A1c; syst. BP, systolic blood pressure.
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compared to Lp-PLA2 activity by atorvastatin. The close 
association between Lp-PLA2 and LDL-C in the circulation 
leads to simultaneous reduction through statin therapy. 
Therefore, the JUPITER trial has shown that on-treatment 
measurement of Lp-PLA2 no longer predicted cardiovas-
cular risk when the participants were treated with rosuv-
astatin [31].
Of note is that the reduction of LDL-C in our patients 
was largely generated by a significant decrease of non-
sdLDL-C during the treatment with atorvastatin, while 
the level of sdLDL-C remained almost unchanged. In a 
recently published study, similar results were seen after 
a 6-month treatment with atorvastatin (10–20 mg/day) 
in adolescents with T1D and elevated LDL-C. In addition 
to the decrease of atherogenic intermediate-density lipo-
protein and very low-density lipoprotein particles, con-
centrations of large, medium, and small LDL subfractions 
were reduced more than very small LDL particles by ator-
vastatin. In contrast to our results, very small dense LDL 
particles were even increased after 6 months of treatment 
with atorvastatin [32]. It has been reported that a 3-month 
treatment with atorvastatin (10 mg/day) in adults with 
heterozygous familial hypercholesterolemia revealed a 
statistically significant reduction of both sdLDL-C and 
large buoyant LDL-C [33]. It should be noted, however, 
that the latter study can only be compared with ours to 
a limited extent mainly because of completely different 
study populations and differing baseline LDL-C profiles. 
Interestingly, however, treatment with human growth 
hormone led to a significant reduction of sdLDL-C in chil-
dren with growth hormone deficiency and children with 
small for gestational age status [34].
It is known that children and adolescents with 
good control of their T1D have the same or even a more 
favorable plasma lipid profile than healthy peers [35]. A 
study involving 98 reasonably well-controlled children 
and adolescents with T1D (mean HbA1c = 8.41%) and 57 
healthy control subjects showed that large LDL particle 
concentration was greater in T1D patients than in con-
trols (p = 0.007). Moreover, controls had higher small 
LDL (p = 0.0067), medium small (p = 0.0026), and very 
small LDL particle concentrations (p = 0.0091) than T1D 
patients [36]. One might speculate that due to the favora-
ble and rather antiatherogenic baseline concentrations of 
triglycerides, HDL-C, total LDL-C, and a comparably low 
proportion of sdLDL-C, no further significant reduction of 
sdLDL-C by atorvastatin could be expected in our equally 
well-controlled T1D patients.
A notable strength of our study is the prospective, pla-
cebo-controlled, double-blind multicenter study design 
including very strict criteria for the inclusion of patients. 
This, in turn, led to the small sample size which is the 
major limitation of the study.
In summary, with these study results, we present new 
data about Lp-PLA2 activity and LDL-subfractions in ado-
lescents with T1D that could be helpful in assessing their 
cardiovascular risk. Furthermore, long-term treatment 
with atorvastatin is safe and may reduce the cardiovascu-
lar risk by significant decreases of Lp-PLA2 activity and 
LDL cholesterol.
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